Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

New Multimode Microplate Reader Delivers High Resolution Performance

By BiotechDaily International staff writers
Posted on 07 Oct 2013
Image: The Mithras2 LB 943 Multimode Monochromator Reader (Photo courtesy of Berthold Technologies).
Image: The Mithras2 LB 943 Multimode Monochromator Reader (Photo courtesy of Berthold Technologies).
A newly available next generation microplate reader performs luminescence, fluorescence, and absorbance measurements with the sensitivity and resolution usually obtained only from separate, dedicated instruments.

The Berthold Technologies (Bad Wildbad, Germany) Mithras2 LB943 microplate reader is a high-end multimode reader based on monochromator technology. The instrument is equipped with two double monochromators with high blocking efficiency and high f-number (increased transmission) for filter free absorbance and fluorescence measurements.

The Mithras2 was designed to carry out an impressive variety of assays including Luminescence, BRET (Bioluminescence Resonance Energy Transfer), fluorescence, FRET (Fluorescence Resonance Energy Transfer), fluorescence polarization (FP), UV/VIS absorbance, time-resolved fluorescence, and time-resolved-FRET. To accomplish these varied tasks the instrument was designed with a proprietary optical system consisting of separate paths for different reading technologies, thus offering quality analysis usually obtained only from separate dedicated instruments.

The instrument can be configured for up to four reagent injectors programmed to dispense multiple activators or detection reagents with user-adjustable volumes at any time during the measurement process. The injectors are based on proprietary JET injection technology that delivers superior accuracy and precision. Variable injections speeds and "bio-friendly" materials enable injection of live cells.

The Mitras2 can be used to measure enzyme activities, phagocytosis, calcium flux, cell viability, apoptosis, immunoassays, protein and nucleic acid concentrations, and protein-protein interactions. Single and multiple endpoint measurements as well as kinetic and scanning measurements can be performed. The data can be displayed numerically and graphically and may be printed or exported to a spreadsheet.

Related Links:

Berthold Technologies




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.